Clinical trials: Myotonic Dystrophy 2
Type 2 Diabetes Mellitus, Myocardial Fibrosis
Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2
There is an unmet need for Cardiovascular Disease (CVD) risk reduction in patients with Type 2 Diabetes. In recent trials there has been promising findings of more effective glucose management and reductions in overall CVD events…
- Conditions
- Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation
- Trial name
- NCT03782259
- Testing
- dapagliflozin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Washington
Myotonic Dystrophy 1
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
The purpose of this study is to determine whether Tideglusib is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy.
- Trial name
- NCT02858908
- Testing
- Tideglusib
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- AMO Pharma Limited
DM1, Myotonic Dystrophy 1
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to…
- Conditions
- DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1)
- Trial name
- MARINA (NCT05027269)
- Testing
- AOC 1001
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Avidity Biosciences, Inc.
Diabetes Mellitus, Type 2, Hypercholesterolemia
Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)
Objective: To investigate the effect of 5 weeks dapagliflozin 10 mg once daily treatment on glucose and lipid fluxes in patients with type 2 diabetes. Study design: Single center single arm (mechanistic) intervention trial.
- Trial name
- DICE (NCT03074630)
- Testing
- Dapagliflozin, Rosuvastatin
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Amsterdam UMC, location VUmc
Diabetes Mellitus
Improving Glycemic Control in DM2 Patients in the Ambulatory Setting
More than 10.5% of the US population has diabetes mellitus. The objective of this pilot study is to evaluate whether smart insulin pens combined with CGM devices can improve glucose control in patients with type 2 diabetes (T2D)
- Trial name
- NCT04800471
- Testing
- Smart insulin pens and CGM, Point of Care Glucose Group
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
End-Stage Renal Disease, Type 2 Diabetes
Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)
The study is conducted to assess the efficacy of real-time CGM data in preventing hypoglycemia in patients with type 2 diabetes and end-stage kidney disease (ESKD), treated with insulin therapy and receiving hemodialysis.
- Trial name
- NCT04473430
- Testing
- Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Emory University